Jimmy Choo Schuhe Our Site is basically your health Advisor

‘Stem Cells Translational Medicine’ Addresses Clinical Trials

Durham, NC (PRWEB) August 02, 2011

STEM CELLS Translational Medicine (SCTM), the latest innovative journal to join the AlphaMed Press’s stable of prestigious medical publications, addresses an acknowledged need within the research and clinical communities for comprehensive clinical coverage of stem cells. As a sister publication to STEM CELLS, the field’s premier journal begun 30 years ago, SCTM will feature high-impact, peer-reviewed articles intended to significantly advance the clinical utilization of stem cell molecular and cellular biology by bridging stem cell research and clinical trials.

Esteemed scientist-clinician and Editor of SCTM, Anthony Atala, MD, explained the rationale for the new publication. “There is no home today for papers based on this field that are translational, so in a way we were on a parallel path as we were 30 years ago when there was no home for stem cell research until AlphaMed launched STEM CELLS,” he said. “SCTM will rectify that by providing a place for these peer-reviewed, excellent papers that deal with the translational aspect of stem cells and regenerative medicine.”

STEM CELLS will continue to focus on the basic laboratory investigations of stem cells. Pioneering researcher Miodrag Stojković, PhD, who also serves as editor of STEM CELLS, added, “Together these two journals will offer researchers and physicians a broad overview of the many exciting discoveries and breakthroughs occurring in this rapidly advancing and ever-more important area of medical research.”

Joining Dr. Atala as Associate Editors are Doug Losordo, MD, Director, Feinberg Cardiovascular Research Institute at Northwestern University and Paolo De Coppi, MD, PhD, Clinical Senior Lecturer and Consultant Paediatric Surgeon at Great Ormond Street Hospital. In collaboration with STEM CELLS, the two editorial boards will identify the very best journal for each high-impact manuscript, providing a home for papers based in stem cell research that are translational to move from managing to curing disease with stem cell, cell therapy and regenerative medicine.

Scheduled to debut this December 2011, SCTM is now accepting online article submissions via ScholarOne Manuscripts (http://mc.manuscriptcentral.com/stemcellstm). Journal sections include:

    Embryonic Stem Cells/Induced Pluripotent Stem (iPS) Cells
    Fetal and Neonatal Stem Cells
    Tissue-Specific progenitor and Stem Cells
    Cell based drug development, screening and toxicology
    Enabling technologies for cell-based clinical translation
    Cancer Stem Cells
    Standards, Policies, and Regulations for cell based therapies
    Protocols and manufacturing for cell based therapies
    Tissue engineering and regenerative medicine

Authors can also download a call-for-papers at http://www.StemCellsTM.com.

About AlphaMed Press – Established in 1983, AlphaMed Press with offices in Durham, NC, Sausalito, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines: STEM CELLS®, now in its 29th year, is the world’s first journal devoted to this fast paced field of research. The Oncologist®, also a monthly peer-reviewed publication, is in its 16th year and is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS Translational Medicine will be available by December 2011. AlphaMed Press publishes the Stem Cells Portal (http://www.StemCellsPortal.com) and The Oncologist Community (http://www.TheOncologistCommunity.com) online, as well as freestanding monographs and books, and is renowned for its excellence and speed in the publication of the peer-reviewed proceedings of major international symposia.

###

©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.